PR

MEZOO, connecting health through technology
Sharing MEZOO’s technology and vision.
External
2026.03.23
Mezoo Aims for 67% Profit Margin as it Penetrates 50% of Top-Tier General Hospitals

[DailyPharm = Reporter Hwang Byung-woo] Mezoo Targets 67% Operating Profit Margin; Eyes Expansion into Half of All General Tertiary Hospitals

Mezoo, a mobile remote patient monitoring (aRPM) company, is seeking to list on the KOSDAQ market with a goal of establishing a profit structure featuring an operating profit margin of approximately 67%. The company’s strategy is to boost profitability by expanding its subscription-based patient monitoring business, leveraging its track record of implementing systems in half of Korea's general tertiary hospitals.

At an IPO press conference held on the 9th, Mezoo presented a strategy to expand its presence in the hospital monitoring market based on its mobile patient monitoring platform, 'HiCardi.'

According to the company's presentation, Mezoo projects it will record 15.4 billion KRW in revenue in 2026, followed by a turnaround to profitability in 2027 with an operating profit of 10.8 billion KRW. By 2029, the company aims to reach 62.7 billion KRW in revenue and 42 billion KRW in operating profit—achieving an operating profit margin of 67%—through the expansion of its subscription-based revenue model.


Beyond the ICU to General Wards: Expanding Mobile Patient Monitoring

Founded in 2007 by Ph.D.s in Biomedical Engineering from Yonsei University’s Wonju Campus, Mezoo possesses core competitiveness in on-device biosignal processing technology.

The company is currently focusing on the mobile remote patient monitoring (aRPM) sector. This focus addresses the limitations of existing hospital monitoring systems, which are primarily centered on Intensive Care Units (ICUs), making it difficult to continuously monitor patient status in general wards.

"In hospitals, it is standard for medical staff to check on patients by making rounds through the wards," explained Park Jung-hwan, CEO of Mezoo. "However, by utilizing a mobile monitoring system, patient status can be checked even when the patient is moving or outside the hospital."

The company explained that remote patient monitoring technology can transform medical service workflows, as it allows medical staff to check patient conditions via a web-based system even when they are off-site.

CEO Park emphasized, "Over the past one to two years, hospitals have begun to seriously consider adopting these systems, and the market is opening up rapidly."

The company estimates the domestic hospital patient monitoring market at approximately 600,000 beds and analyzed that the market is currently in its early stages, with the adoption rate of digital monitoring systems at only about 3%.


Source : https://www.dailypharm.com/user/news/336316

적용 법률 및 규정
의료기기

하이카디® 시스템은 인허가에 따라 신생아, 소아, 청소년, 18세 이상 환자의 ECG 데이터를 측정하여 부정맥을 진단하는 의료기기로서 의료전문가가 사용하도록 설계되었습니다. 한국 KFDA로부터 의료기기 2등급 인증을 받았습니다. 유럽의료기기 지침(2007/47/EC에 따라 개정된 MDD 93/42/EEC)에 따라 준수된 Class IIb (CE2265). 의료기기 제품으로 CE 승인되었습니다. 미국 FDA는 Class II 510K로 승인 완료 예정입니다.

경고

본 자료는 의료 전문가에게만 배포되며 관련 사진과 함께 제공되는 자료와 관련하여 그 어떤 법적인 책임을 갖지 않습니다. 사용 전 사용 지침서를 주의 깊게 읽으십시오.